Jeffrey A. Bluestone is the former President and Chief Executive Officer of Sonoma Biotherapeutics and has served as an independent director of Gilead since 2020. He is an internationally recognized leader in immunotherapy and related fields with a scientific and academic career spanning four decades and strong leadership experience in the healthcare industry.